Current Issue : April - June Volume : 2020 Issue Number : 2 Articles : 5 Articles
Infectious diseases continue to be a significant cause of morbidity and mortality, and\nalthough efficacious vaccines are available for many diseases, some parenteral vaccines elicit little\nor no mucosal antibodies which can be a significant problem since mucosal tissue is the point of\nentry for 90% of pathogens. In order to provide protection for both serum and mucosal areas, we\nhave tested a combinatorial approach of both parenteral and oral administration of antigens for\ndiseases caused by a viral pathogen, Hepatitis B, and a fungal pathogen, Coccidioides. We\ndemonstrate that co-administration by the parenteral and oral routes is a useful tool to increase the\noverall immune response. This can include achieving an immune response in tissues that are not\nelicited when using only one route of administration, providing a higher level of response that can\nlead to fewer required doses or possibly providing a better response for individuals that are\nconsidered poor or non-responders....
Objective. Hypothyroid patients are treated by sodium levothyroxine (LT4). Tablet is the mostly used LT4 formulation, and the\nfasting regimen is required for the absorption of active principle. Also, gastrointestinal diseases and drugs may impair the LT4\nbioavailability when tablet is used. Nonsolid LT4 formulations (i.e., liquid solution (LS) and soft gel (SG) capsule) were\nmanufactured to overcome the limitations of LT4 tablet. This study was conceived to evaluate the performance of nonsolid LT4\nformulations in a real-life scenario. Methods. Two institutions participated in the study that was conducted in two phases (i.e.,\nenrollment and re-evaluation). Adults with autoimmune or postsurgical hypothyroidism and on LT4 from a few months were\nselected. A nonparametric statistical analysis for paired or unpaired data was performed. Results. 121 consecutive cases were\nincluded. At the enrollment phase, a 52% of patients took the therapy at least 30 min before breakfast with no difference between\ntablet and SG/LS users.................................
Aim. To assess the effect of treating chronic hepatitis C virus (HCV) infection with direct acting antiviral drugs (DAAs) on glycemic\ncontrol in patients with concomitant diabetes mellitus (DM). Methods. We performed a retrospective case-control study in a viral\nhepatitis ambulatory clinic in Shreveport, Louisiana, during the period 11/01/2014 to 12/31/2017. All the clinic patient ages 18 years\nand above with treatment-naïve/biopsy-proven chronic hepatitis C and DM����....
Chronic hepatitis B (CHB) is the cause of severe liver damage, cirrhosis, and hepatocellular\ncarcinoma for over 240 million people worldwide. Nowadays, several types of treatment are being\ninvestigated, including immunotherapy using hepatitis B core antigen (HBcAg) assembled into\nhighly immunogenic capsid-like particles (CLPs). Immunogenicity of plant-produced and purified\nHBcAg, administered parenterally or intranasally, was previously reported. In this study, a novel\nparenteralâ??oral vaccination scheme is proposed using plant-derived HBcAg preparations. The antigen\nfor injection was obtained via transient expression in Nicotiana benthamiana. HBcAg-producing\ntransgenic lettuce was lyophilized and used as an orally delivered booster. ..............
Signal regulatory protein Alpha (SIRPAlpha), a transmembrane protein that is predominantly expressed in dendritic cells (DCs) or\nmacrophages, interacts with CD47 that is overexpressed in almost all types of tumor cells. The interaction between SIRPAlpha and\nCD47 leads to a negative signal that prevents the phenotypic and functional maturation of DC and inhibits phagocytosis. The\nSIRPAlpha knockdown in DCs that were pulsed with a modified HPV16E7 (HPV16mE7) protein with enhanced antigenicity and\nreduced transformation activity results in increased cytokine (TNF-Alpha/IL-12/IL-6) secretion, IFN-Gamma secretion by T lymphocytes,\nand in vitro/in vivo tumoricidal activity against cervical cancer cells. Taken together, these results suggest that SIRPAlpha-silenced\nDC vaccination presented potential therapeutic implications against cervical cancer....
Loading....